Clinical trials: Diabetic Retinopathy, completed
Macular Edema
Safety and Efficacy Study of Dexamethasone Versus Ranibizumab in Patients With Diabetic Macular Edema
This study will compare the safety and efficacy of the 700 ug dexamethasone intravitreal implant with ranibizumab 0.5 mg intravitreal injections in patients with diabetic macular edema (DME).
- Trial name
- NCT01492400
- Testing
- dexamethasone Intravitreal Implant, ranibizumab
- Where
- 13 sites in United States, Belgium and 10 more
- Volunteers
- 363 people
- Sponsor
- Allergan
Diabete Type 2, Cataract
Corticosteroid Injection Combined With Cataract Surgery in Diabetic Eyes.
The investigators aim in this study to investigate the effect of intravitreal triamcinolone acetonide injection on the development of macular edema and the progression of diabetic retinopathy.
- Conditions
- Diabete Type 2, Cataract, Triamcinolone Acetonide, Intravitreal Injection
- Trial name
- NCT05413330
- Testing
- Triamcinolone Acetonide
- Where
- Syria
- Volunteers
- 73 people
- Sponsor
- Damascus University
Diabetic Retinopathy
The Comparative Effectiveness of Telemedicine to Detect Diabetic Retinopathy
This project aims to: 1) evaluate the long-term effectiveness of telemedicine to detect diabetic retinopathy when compared to traditional surveillance methods, 2) identify the health belief factors related to adherence with…
- Trial name
- NCT01364129
- Testing
- Ophthalmic Telemedicine
- Where
- 2 sites in United States
- Volunteers
- 567 people
- Sponsor
- Legacy Health System
Diabetic Retinopathy
Diabetic Retinopathy Sulodexide Study
The aim of this phase 2 controlled placebo study is to assess the effectiveness of Sulodexide in the treatment of non proliferative (background) retinopathy in patients with Type 1 and Type 2 Diabetes Mellitus.
- Trial name
- DRESS (NCT01295775)
- Testing
- sulodexide
- Where
- South Korea
- Volunteers
- 127 people
- Sponsor
- Ajou University School of Medicine
Diabetic Retinopathy, Macular Edema
Treatment of Diabetic Macular Edema With Aflibercept in Subjects Previously Treated With Ranibizumab or Bevacizumab
Treatment of diabetic macular edema with intravitreal aflibercept in subjects previously treated with intravitreal anti-Vascular endothelial growth factor (VEGF) agents (ranibizumab or bevacizumab)
- Trial name
- SwapTwo (NCT02559180)
- Testing
- aflibercept
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Rishi Singh
Non-Proliferative Diabetic Retinopathy
A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy
A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.
- Trial name
- NCT02435862
- Testing
- 1.0mg Luminate®, 2.0mg Luminate®, 3.0mg Luminate®
- Where
- 12 sites in United States
- Volunteers
- 105 people
- Sponsor
- Allegro Ophthalmics, LLC
Proliferative Diabetic Retinopathy
Vitreous Levels of Cysteine-rich 61 in Patients With Proliferative Diabetic Retinopathy
To determine the vitreous levels of fractalkine, cysteine-rich 61 (Cyr61), and VEGF in patients with PDR. Verifying that it is greater to that found in non-diabetic patients with different non-angiogenetic diseases.
- Trial name
- VL (NCT01920984)
- Testing
- intravitreal injection of 1.25 mg of bevacizumab
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Diabetic Nephropathy, Diabetic Retinopathy
Anti-Nephropathic Effects of Chronic Intermittent Intravenous Insulin Therapy (CIIIT)
Investigators with the goal of optimizing glycemic and blood pressure control saw type 1 diabetic patients weekly. A control group received 3-4 subcutaneous insulin injections per day; an intravenous insulin pulsed infusion group…
- Trial name
- NCT00594152
- Testing
- CIIIT
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Joslin Diabetes Center
Type-2 Diabetes, Diabetic Retinopathy
Phenotypes of Nonproliferative Diabetic Retinopathy in DM 2 Patients Identified by OCT, CFP, RLA and mfERG (DIAMARKER)
To characterise phenotypes of Non Proliferative Diabetic Retinopathy (NPDR) progression using multimodal testing/imaging procedures.
- Trial name
- NCT01440660
- Where
- Portugal
- Volunteers
- 20 people
- Sponsor
- Association for Innovation and Biomedical Research on Light and Image
Diabetic Retinopathy
Evaluation of the Retina of Subjects Without Diabetes Mellitus and Subjects With Diabetes Mellitus Without Diabetic Retinopathy Using Optical Coherence Tomography
The purpose of this study is to evaluate topographic features of the posterior pole of the eye in normal subjects as well as in subjects with diabetes mellitus but without diabetic retinopathy (DR) using optical coherence…
- Trial name
- NCT01946997
- Testing
- OCT Imaging both Normal and diabetic groups
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Diabetic Retinopathy
A Phase 2 Evaluation of Anti-VEGF Therapy for Diabetic Macular Edema: Bevacizumab (Avastin)
This study will provide preliminary data on the dose and dose interval related effects of intravitreally administered Avastin on retinal thickness and visual acuity in subjects with Diabetic Macular Edema (DME) to aid in planning…
- Trial name
- Bevacizumab (NCT00336323)
- Testing
- Laser Photocoagulation, Bevacizumab
- Where
- 34 sites in United States
- Volunteers
- 121 people
- Sponsor
- Jaeb Center for Health Research
Proliferative Diabetic Retinopathy
PRP vs Bevacizumab for PDR Treatment
Protocol S by DRCR.net has shown that receive Ranibizumab as anti-vascular endothelial growth factor (anti-VEGF) therapy with deferred panretinal photocoagulation (PRP) are non-inferior to those in eyes that receive standard…
- Trial name
- NCT02705274
- Testing
- Bevacizumab, Panretinal photocoagulation
- Where
- Syria
- Volunteers
- 30 people
- Sponsor
- Marashi Eye Clinic
Diabetic Retinopathy, Vitreous Hemorrhage
Preoperative Bevacizumab for Vitreous Hemorrhage
The purpose of this study is to determine whether preoperative intravitreal bevacizumab is effective in reducing intra-operative and postoperative bleeding in diabetic patients submitted to pars plana vitrectomy for vitreous…
- Trial name
- IBEVI (NCT00596297)
- Testing
- bevacizumab, pars plana vitrectomy
- Where
- Brazil
- Volunteers
- 16 people
- Sponsor
- University of Sao Paulo
Compliance, Diabetic Retinopathy
a Trial of Using SMS Reminder Among Diabetic Retinopathy Patients in Rural China
The purpose of this study is to use a randomized controlled design to determine the impact of a SMS messaging intervention on the following outcomes among persons diagnosed with diabetic retinopathy in rural China.
- Conditions
- Compliance, Diabetic Retinopathy, SMS
- Trial name
- SMS (NCT01837121)
- Testing
- the SMS reminder message
- Where
- China
- Volunteers
- 237 people
- Sponsor
- Sun Yat-sen University
Pseudophakic Cystoid Macular Edema,, Diabetic Macular Edema
Ozurdex for Combined Pseudophakic Cystoid Macular Edema and Diabetic Macular Edema After Cataract Surgery
The purpose of the study is to determine where a sustained steroid delivery system (Ozurdex,Allergan) is safe and effective to treat Cystoid Macular Edema in diabetic patients after Cataract Surgery
- Trial name
- NCT01284478
- Testing
- Dexamethasone Implant
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Northern California Retina Vitreous Associates
Diabetic Retinopathy
SLMAP and EPO Genetic Polymorphism in Diabetic Retinopathy
A case-control study to assess the association between the risk of diabetic retinopathy in Egyptians and genetic polymorphism of both EPO and SLMAP genes.
- Trial name
- NCT05344690
- Testing
- SLMAP and EPO genetic polymorphism
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Ain Shams University
Diabetic Retinopathy
Octreotide Acetate in Microspheres in Patients With Diabetic Retinopathy
The most common ocular disease in patients with diabetes, diabetic retinopathy, is present in approximately 40% of diabetic patients; about 8% of diabetic patients have vision threatening diabetic retinopathy.
- Trial name
- NCT00131144
- Testing
- Octreotide Acetate in Microspheres 20 mg, Octreotide Acetate in Microspheres
- Where
- United States
- Volunteers
- 583 people
- Sponsor
- Novartis
Diabetic Macular Edema, Retinal Disease
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema.
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus
- Trial name
- NCT06011798
- Testing
- Aflibercept, foselutoclax
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Macular Edema
Safety, Efficacy and Cost-efficacy of Ranibizumab (Monotherapy or Combination With Laser) in the Treatment of Diabetic Macular Edema (DME)
To evaluate, specifically within the Canadian medical environment, the efficacy, safety and cost-efficacy of ranibizumab administered either as combination therapy (ranibizumab plus laser photocoagulation), or as monotherapy in…
- Trial name
- RESPOND (NCT01135914)
- Testing
- ranibizumab, Laser
- Where
- 20 sites in Canada
- Volunteers
- 241 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema
Suprachoroidal Sustained-Release OXU-001 Compared to Intravitreal Ozurdex® in the Treatment of Diabetic Macular Edema
The purpose of this clinical trial is to compare safety, tolerability, efficacy, and durability of two dose levels of suprachoroidal sustained-release OXU-001 (dexamethasone microspheres; DEXAspheres®) using the Oxulumis®…
- Trial name
- OXEYE (NCT05697809)
- Testing
- OXU-001, Semi-automated suprachoroidal illuminated microcatheter, Ozurdex® Ophthalmic Intravitreal Implant
- Where
- 9 sites in United States, Puerto Rico
- Volunteers
- 3 people
- Sponsor
- Oxular Limited